Akero Therapeutics, Inc. (AKRO)
54.65
0.00 (0.00%)
USD |
NASDAQ |
Dec 11, 16:00
Akero Therapeutics Research and Development Expense (Quarterly): 78.88M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.492B |
| Eli Lilly & Co. | 3.466B |
| Bristol Myers Squibb Co. | 2.433B |
| Adaptive Biotechnologies Corp. | 20.92M |
| Johnson & Johnson | 3.693B |